On July 23 and 24, the FDA will hold a meeting. By the time it's over, a large number of people will believe things about it that aren't true. Today's Memo is so you aren't one of them.
What is actually happening:
The FDA is convening the Pharmacy Compounding Advisory Committee: an outside panel of experts to discuss whether seven specific peptides should be added to a list called Category 1. Category 1 is the list of substances that compounding pharmacies are allowed to prepare while the FDA continues to evaluate them. These seven peptides were moved to a more restricted list (Category 2) in 2023. A second meeting, covering five more peptides, will happen before the end of February 2027.
What is not happening:
Peptides are not being "legalized." They were never illegal in any criminal sense. What's being debated is whether a specific class of licensed pharmacies can, under a specific federal framework, prepare specific compounds for specific patients with valid prescriptions. That is a narrower question than it sounds.
The meeting is also not a vote that takes effect immediately. Advisory panels recommend. The FDA decides. If the FDA agrees with the panel, it then has to draft and publish formal rules. The head of a major compounding pharmacy group has already described what's coming as "a protracted process." Translation: even the optimistic version of this takes months to fully play out.
Three things to watch for:
One: How the panel is composed. The FDA's pharmacy advisory panel has had vacancies that the current administration has the power to fill. Who sits at the table changes what comes out of it.
Two: Which seven peptides are on the July agenda,and which aren't. The seven under review in July are expected to be the ones with the strongest existing safety data. The five being held for 2027 are a signal: those are the ones with more unresolved questions. When the list becomes official, it will tell you a lot about what the FDA thinks of each compound.
Three: The dissenting voices. The original 2023 decision to restrict these peptides cited real safety concerns. Cancer risk, liver and kidney issues, heart problems, limited human testing. Those concerns haven't been retracted. Expect former FDA officials and medical associations to push back hard. Their arguments will be louder in the weeks after the meeting than during it.
What the headlines will get wrong:
Some will say peptides are now "legal." Others will say the FDA has "approved" them. Both are wrong. Reclassification to Category 1 allows compounding under continued evaluation. FDA approval is a completely separate process requiring full clinical trials. We will be keeping this distinction front-and-center until the rest of the coverage catches up.
What to actually do with this information:
If you've been considering peptides, nothing about this meeting changes your situation in July. Access still requires a physician, a prescription, and a licensed compounding pharmacy. What the meeting changes is the market: who's preparing to sell, who's preparing to prescribe, who's preparing to invest. That's where the next few Memos will focus.
Next week: BPC-157, the peptide everyone wants to talk about.
— The Peptide Memo